|Bid||2.7700 x 0|
|Ask||2.7800 x 0|
|Day's Range||2.7300 - 2.8400|
|52 Week Range||2.3600 - 6.0600|
|Beta (5Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.71|
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021, at 8:00 a.m. ET to discuss a corporate update and financial results for the third quarter of 2021.
Announced that its partner Adlai Nortye has initiated dosing in a bridging clinical trial evaluating ...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has initiated dosing in a bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.